These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 31463794

  • 1. Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis.
    Kisla Ekinci RM, Balci S, Dogruel D, Altintas DU, Yilmaz M.
    Paediatr Drugs; 2019 Oct; 21(5):389-395. PubMed ID: 31463794
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
    Varan Ö, Kucuk H, Babaoglu H, Guven SC, Ozturk MA, Haznedaroglu S, Goker B, Tufan A.
    Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Canakinumab treatment in children with familial Mediterranean fever: report from a single center.
    Yazılıtaş F, Aydoğ Ö, Özlü SG, Çakıcı EK, Güngör T, Eroğlu FK, Gür G, Bülbül M.
    Rheumatol Int; 2018 May; 38(5):879-885. PubMed ID: 29450637
    [Abstract] [Full Text] [Related]

  • 5. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
    Eroglu FK, Beşbaş N, Topaloglu R, Ozen S.
    Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review.
    Eren Akarcan S, Dogantan S, Edeer Karaca N, Aksu G, Kutukculer N.
    Rheumatol Int; 2020 Jan; 40(1):161-168. PubMed ID: 31273456
    [Abstract] [Full Text] [Related]

  • 9. Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever.
    Laskari K, Boura P, Dalekos GN, Garyfallos A, Karokis D, Pikazis D, Settas L, Skarantavos G, Tsitsami E, Sfikakis PP.
    J Rheumatol; 2017 Jan; 44(1):102-109. PubMed ID: 28042127
    [Abstract] [Full Text] [Related]

  • 10. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
    Şahin A, Derin ME, Albayrak F, Karakaş B, Karagöz Y.
    Adv Rheumatol; 2020 Jan 30; 60(1):12. PubMed ID: 32000860
    [Abstract] [Full Text] [Related]

  • 11. Familial Mediterranean fever in childhood: a single-center experience.
    Barut K, Sahin S, Adrovic A, Sinoplu AB, Yucel G, Pamuk G, Aydın AK, Dasdemir S, Turanlı ET, Buyru N, Kasapcopur O.
    Rheumatol Int; 2018 Jan 30; 38(1):67-74. PubMed ID: 28828621
    [Abstract] [Full Text] [Related]

  • 12. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
    Özçakar ZB, Özdel S, Yılmaz S, Kurt-Şükür ED, Ekim M, Yalçınkaya F.
    Clin Rheumatol; 2016 Feb 30; 35(2):441-6. PubMed ID: 25213327
    [Abstract] [Full Text] [Related]

  • 13. Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases.
    Çakan M, Karadağ ŞG, Ayaz NA.
    Turk J Pediatr; 2020 Feb 30; 62(2):167-174. PubMed ID: 32419407
    [Abstract] [Full Text] [Related]

  • 14. Long-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patients.
    Gülez N, Makay B, Sözeri B.
    Mod Rheumatol; 2020 Jan 30; 30(1):166-171. PubMed ID: 30556769
    [Abstract] [Full Text] [Related]

  • 15. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment.
    Karabulut Y, Gezer HH, Duruöz MT.
    Rheumatol Int; 2022 Jan 30; 42(1):81-86. PubMed ID: 34550430
    [Abstract] [Full Text] [Related]

  • 16. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
    De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, Koné-Paut I, Lachmann HJ, Ozen S, Simon A, Zeft A, Calvo Penades I, Moutschen M, Quartier P, Kasapcopur O, Shcherbina A, Hofer M, Hashkes PJ, Van der Hilst J, Hara R, Bujan-Rivas S, Constantin T, Gul A, Livneh A, Brogan P, Cattalini M, Obici L, Lheritier K, Speziale A, Junge G.
    N Engl J Med; 2018 May 17; 378(20):1908-1919. PubMed ID: 29768139
    [Abstract] [Full Text] [Related]

  • 17. Canakinumab treatment in four children with colchicine resistant familial mediterranean fever.
    Ozkan S, Atas B.
    J Pak Med Assoc; 2017 Jun 17; 67(6):945-947. PubMed ID: 28585601
    [Abstract] [Full Text] [Related]

  • 18. Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series.
    Sendogan DO, Saritas H, Kumru G, Eyupoglu S, Sadioglu RE, Tuzuner A, Sengul S, Keven K.
    Transplant Proc; 2019 Sep 17; 51(7):2292-2294. PubMed ID: 31400972
    [Abstract] [Full Text] [Related]

  • 19. An "On Demand" canakinumab regimen for treating children with Colchicine-Resistant familial Mediterranean fever - A multicentre study.
    Shehadeh K, Levinsky Y, Kagan S, Zuabi T, Tal R, Aviran NH, Butbul Aviel Y, Tirosh I, Spielman S, Miller-Barmak A, Semo Oz R, Harel L, Chodick G, Amarilyo G.
    Int Immunopharmacol; 2024 May 10; 132():111967. PubMed ID: 38569431
    [Abstract] [Full Text] [Related]

  • 20. The effect of canakinumab treatment on growth parameters in children with familial Mediterranean fever.
    Aydin EA, Baglan E, Kocamaz NG, Bagrul İ, Tuncez S, Ozdel S.
    Clin Rheumatol; 2024 Jan 10; 43(1):387-392. PubMed ID: 37658934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.